Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Daijiro Abe is active.

Publication


Featured researches published by Daijiro Abe.


Bone Marrow Transplantation | 2009

Successful combination treatment with bevacizumab, thalidomide and autologous PBSC for severe POEMS syndrome

Chikako Ohwada; Chiaki Nakaseko; Shio Sakai; Yusuke Takeda; Daijiro Abe; Masahiro Takeuchi; Emiko Sakaida; Shinichi Masuda; Naomi Shimizu; Ryuko Cho; Miki Nishimura; Kazuaki Kanai; Sonoko Misawa; Satoshi Kuwabara

Successful combination treatment with bevacizumab, thalidomide and autologous PBSC for severe POEMS syndrome


Blood | 2008

Restrictive usage of monoclonal immunoglobulin λ light chain germline in POEMS syndrome

Daijiro Abe; Chiaki Nakaseko; Masahiro Takeuchi; Chikako Ohwada; Emiko Sakaida; Yusuke Takeda; Kayo Oda; Shinichi Ozawa; Naomi Shimizu; Shinichi Masuda; Ryuko Cho; Miki Nishimura; Sonoko Misawa; Satoshi Kuwabara; Yasushi Saito

POEMS syndrome is a rare plasma cell disorder characterized by peripheral neuropathy, monoclonal gammopathy, and high levels of serum vascular endothelial growth factor, the pathogenesis of which remains unclear. A unique feature of this syndrome is that the proliferating monoclonal plasma cells are essentially lambda-restricted. Here we determined complete nucleotide sequences of monoclonal immunoglobulin lambda light chain (IGL) variable regions in 11 patients with POEMS syndrome. The V-region of the Ig lambda gene of all 11 patients was restricted to the V lambda 1 subfamily. Searching for homologies with IGL germlines revealed that 2 germlines, IGLV1-44*01 (9/11) and IGLV1-40*01 (2/10), were identified, with an average homology of 91.1%. The IGLJ3*02 gene was used in 11 of 11 re-arrangements with an average homology of 92.2%. These data suggest that the highly restricted use of IGL V lambda 1 germlines plays an important role in the pathogenesis of POEMS syndrome.


Transplant Infectious Disease | 2013

Severe hyponatremia caused by syndrome of inappropriate secretion of antidiuretic hormone developed as initial manifestation of human herpesvirus‐6–associated acute limbic encephalitis after unrelated bone marrow transplantation

Takeharu Kawaguchi; Masahiro Takeuchi; Chika Kawajiri; Daijiro Abe; Yuhei Nagao; Atsuko Yamazaki; Yasumasa Sugita; Shokichi Tsukamoto; Shio Sakai; Yusuke Takeda; Chikako Ohwada; Emiko Sakaida; Naomi Shimizu; Koutaro Yokote; Tohru Iseki; Chiaki Nakaseko

Severe hyponatremia is a critical electrolyte abnormality in allogeneic stem cell transplantation (allo‐SCT) recipients and >50% of cases of severe hyponatremia are caused by the syndrome of inappropriate secretion of antidiuretic hormone (SIADH). Here, we present a patient with rapidly progressive severe hyponatremia as an initial sign and symptom of human herpesvirus‐6–associated post‐transplantation acute limbic encephalitis (HHV‐6 PALE) after allo‐SCT. A 45‐year‐old woman with acute lymphoblastic leukemia received unrelated bone marrow transplantation from a one locus‐mismatched donor at the DR locus. On day 21, she developed a generalized seizure and loss of consciousness with severe hyponatremia, elevated serum antidiuretic hormone (ADH), and decreased serum osmolality. A high titer of HHV‐6 DNA was detected in cerebrospinal fluid. Treatment with foscarnet sodium and hypertonic saline was started with improvement of neurological condition within several days. Although an elevated serum ADH, low serum osmolality, and high urinary osmolality persisted for 2 months, she had no other recurrent symptoms of encephalitis. Our experience suggests that hyponatremia accompanied by SIADH should be recognized as a prodromal or concomitant manifestation of HHV‐6 PALE, and close monitoring of serum sodium levels in high‐risk patients for HHV‐6 PALE is necessary for immediate diagnosis and treatment initiation.


Bone Marrow Transplantation | 2012

Factors associated with the efficiency of PBSC collection in POEMS syndrome patients undergoing autologous PBSC transplantation

Naomi Shimizu; Chiaki Nakaseko; Emiko Sakaida; Chikako Ohwada; Masahiro Takeuchi; Takeharu Kawaguchi; Shokichi Tsukamoto; Shio Sakai; Yusuke Takeda; Daijiro Abe; Koutaro Yokote; Tohru Iseki; Kazuaki Kanai; Sonoko Misawa; Satoshi Kuwabara

Factors associated with the efficiency of PBSC collection in POEMS syndrome patients undergoing autologous PBSC transplantation


Bone Marrow Transplantation | 2007

Successful engraftment by second cord blood transplantation with reduced-intensity conditioning after graft rejection due to hemophagocytic syndrome following initial CBT

H Tanaka; Chikako Ohwada; Emiko Sakaida; Yusuke Takeda; Daijiro Abe; K Oda; S Ozawa; Norio Shimizu; Shinichi Masuda; Ryuko Cho; Miki Nishimura; Yasushi Saito; Chiaki Nakaseko

Successful engraftment by second cord blood transplantation with reduced-intensity conditioning after graft rejection due to hemophagocytic syndrome following initial CBT


Bone Marrow Transplantation | 2011

Low-dose trimethoprim-sulfamethoxazole for Pneumocystis jiroveci pneumonia prophylaxis after allogeneic hematopoietic SCT.

Tomoya Muto; Masahiro Takeuchi; Takeharu Kawaguchi; Satomi Tanaka; Shokichi Tsukamoto; Shio Sakai; Yusuke Takeda; Daijiro Abe; Chikako Ohwada; Emiko Sakaida; Naomi Shimizu; Kotaro Yokote; Tohru Iseki; Chiaki Nakaseko

Low-dose trimethoprim–sulfamethoxazole for Pneumocystis jiroveci pneumonia prophylaxis after allogeneic hematopoietic SCT


Clinical Therapeutics | 2010

Super-acute onset of tumor lysis syndrome accompanied by hypercytokinemia during treatment of Hodgkin's lymphoma with ABVD chemotherapy

Takaaki Suzuki; Masahiro Takeuchi; Hiromi Saeki; Shingo Yamazaki; Hitomi Koga; Daijiro Abe; Miki Nishimura; Chiaki Nakaseko; Hiromitsu Nakasa; Hiroyoshi Nakamura; Noritaka Ariyoshi; Mitsukazu Kitada

BACKGROUND Tumor lysis syndrome (TLS) is a group of life-threatening metabolic complications that can occur after initiation of cancer chemotherapy. Onset of TLS in the middle of chemotherapy, however, has not been reported previously in patients with hematologic malignancies. OBJECTIVE We report a case of a patient who experienced TLS of super-acute onset accompanied by hypercytokinemia during chemotherapy treatment with a combination of doxorubicin (Adriamycin), bleomycin, vinblastine, and dacarbazine (ABVD). CASE SUMMARY A 36-year-old Japanese man (height, 182 cm; weight, 83 kg; body surface area, 2.04 m(2)) was admitted to the hospital for the treatment of malignant lymphoma (clinical stage IVB Hodgkins lymphoma). Chemotherapy was initiated using the ABVD regimen (doxorubicin [Adriamycin] 25 mg/m(2) by 30-minute infusion, bleomycin 9 mg/m(2) by 30-minute infusion, vinblastine 6 mg/m(2) by bolus injection, and dacarbazine 375 mg/m(2) by 2-hour infusion). During the dacarbazine infusion, the patients body temperature rose from 36.5 degrees C to 42 degrees C; he experienced a convulsion and then lost consciousness. The convulsion was not suppressed despite the use of diazepam (5 mg IV twice) and phenytoin (500 mg IV). The patient was then transferred to the intensive care unit and sedated using a continuous infusion of midazolam (10 mg/h). Levels of serum lactate dehydrogenase, aspartate aminotransferase, uric acid, blood urea nitrogen, and creatinine evaluated shortly after the ABVD regimen were outside normal limits. In addition, interleukin-6 (IL-6) concentrations were elevated to 54,220 pg/mL. Continuous hemodiafiltration was immediately performed to lower the elevated levels of IL-6. The next day, IL-6 concentrations decreased to 97 pg/mL, and the patient was weaned from ventilator support and sedation. The patient had no adverse effects after the event. According to the results of an assessment using the Naranjo adverse drug reaction probability scale (score = 3), the development of TLS in this patient was possibly related to the chemotherapy regimen. CONCLUSIONS ABVD chemotherapy was possibly associated with the super-acute onset of TLS in this patient. In addition, hypercytokinemia occurred with TLS, which led to pyrexia, convulsion, and loss of consciousness.


Clinica Chimica Acta | 2016

Prognostic impact of serum soluble LR11 in newly diagnosed diffuse large B-cell lymphoma: A multicenter prospective analysis

Yasumasa Sugita; Chikako Ohwada; Takeharu Kawaguchi; Tomoya Muto; Shokichi Tsukamoto; Yusuke Takeda; Naoya Mimura; Masahiro Takeuchi; Emiko Sakaida; Naomi Shimizu; Daijiro Abe; Motoharu Fukazawa; Takeaki Sugawara; Nobuyuki Aotsuka; Kaichi Nishiwaki; Katsuhiro Shono; Hiroyuki Ebinuma; Kengo Fujimura; Hideaki Bujo; Koutaro Yokote; Chiaki Nakaseko

BACKGROUND LR11 (also called SorLA or SORL1) is a type I membrane protein, originally identified as a biomarker for atherosclerosis and Alzheimers disease. We recently found that LR11 was specifically expressed in Diffuse Large B-cell lymphoma (DLBCL) cells, and high serum sLR11 concentrations in retrospective cohort indicated inferior survival. In this study, we prospectively validated the clinical impact of serum sLR11 in 97 patients with newly-diagnosed, untreated DLBCL. RESULTS Serum sLR11 concentrations were increased in DLBCL patients compared to normal controls (mean±SD: 21.2±27.6 vs. 8.8±1.8ng/ml, P<0.0001), and significantly reduced at remission (mean±SD: 17.4±16.4 vs. 10.9±4.5ng/ml, P=0.02). Increased serum sLR11 concentrations were affected by tumor burden and bone marrow invasion. The 2-y OS and PFS were significantly lower in patients with high sLR11 concentrations (≤18.1ng/ml vs. >18.1ng/ml; 2-y OS: 89.0% vs. 56.4%, P<0.0001; 2-y PFS: 85.8% vs. 56.9%, P<0.0001). CONCLUSIONS Serum sLR11 is a tumor-derived biomarker for predicting the survival of newly diagnosed patients with DLBCL.


Bone Marrow Transplantation | 2011

Successful treatment with rituximab and donor lymphocyte infusions for fulminant EBV-associated lymphoproliferative disorder that developed 14 years after unrelated BMT.

Takeharu Kawaguchi; Shokichi Tsukamoto; Chikako Ohwada; Masahiro Takeuchi; Tomoya Muto; Satomi Tanaka; Shio Sakai; Yusuke Takeda; Daijiro Abe; Emiko Sakaida; Norio Shimizu; Kotaro Yokote; Tohru Iseki; Ken-Ichi Imadome; Chiaki Nakaseko

Successful treatment with rituximab and donor lymphocyte infusions for fulminant EBV-associated lymphoproliferative disorder that developed 14 years after unrelated BMT


Bone Marrow Transplantation | 2007

Successful matched unrelated BMT for secondary AML which developed simultaneously with relapsed Hodgkin's lymphoma

Chikako Ohwada; Chiaki Nakaseko; H Tanaka; Daijiro Abe; K Oda; S Ozawa; Masahiro Takeuchi; Norio Shimizu; Ryuko Cho; Yasushi Saito; Miki Nishimura

Successful matched unrelated BMT for secondary AML which developed simultaneously with relapsed Hodgkins lymphoma

Collaboration


Dive into the Daijiro Abe's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge